Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 14/20 | 0.78 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.71 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414297 | 0.88 | DRD2 (0.78) | DRD2DRD4HRH4DRD1PAK1 | |
| SCHEMBL20369209 | 0.87 | DRD2 (0.77) | DRD2DRD4HRH4DRD1PAK1 | |
| SCHEMBL11925297 | 0.86 | DRD2 (0.75) | DRD2DRD4HRH4DRD1 | |
| SCHEMBL7409000 | 0.85 | HRH4 (0.74) | DRD2DRD4HRH4DRD1PAK1 | |
| SCHEMBL11634301 | 0.84 | DRD2 (0.72) | DRD2DRD4HRH4DRD1PAK1 | |
| SCHEMBL14133031 | 0.83 | DRD2 (0.71) | DRD2DRD4HRH4DRD1 | |
| SCHEMBL22077139 | 0.82 | DRD2 (0.69) | DRD2DRD4HRH4DRD1 | |
| SCHEMBL9872948 | 0.81 | DRD1 (1.00) | DRD2DRD4DRD1 | |
| SCHEMBL25462854 | 0.79 | MAPK1 (0.73) | DRD2DRD4HRH4DRD1 | |
| Perchlorate SCHEMBL11631964 | 0.78 | DRD2 (0.64) | DRD2DRD4HRH4DRD1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655314-B1 | MULTI-API LOADING PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2018-02-07 | — | — | EP | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2008050341-A2 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885DRD4 301/4885HRH4 870/4885 |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | HTT, HNMT, GAP43 | DRD2 2057/4885DRD4 1952/4885HRH4 147/4885 |
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | DRD2 3840/4885DRD4 4140/4885HRH4 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.